Department of Medical Laboratories Techniques, Al-Mustaqbal University College, Hillah, Babylon, Iraq.
College of Dentistry, Wasit University, Al-Kut, Wasit, Iraq.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Oct;396(10):2261-2267. doi: 10.1007/s00210-023-02503-8. Epub 2023 Apr 29.
Peptic ulcer disease (PUD) continues to be a cause of significant morbidity and mortality worldwide. Almost two-thirds of PUD cases are asymptomatic. In symptomatic patients, epigastric pain is the most common presenting symptom of PUD, which is manifested by nausea, abdominal fullness, bloating, and dyspepsia. Most PUD cases are associated with the use of COX inhibitors or Helicobacter pylori infection, or both. The traditional management of PUD includes the use of proton pump inhibitors to reduce the gastric acid secretion and antibacterial drugs to combat H. pylori. Timely diagnosis and treatment of PUD are vital to reduce the risk of associated morbidity and mortality, as is prevention of PUD among patients at high risk, including COX inhibitors users and those infected with H. pylori. PDE5 inhibitors have been used for the management of erectile dysfunction and pulmonary hypertension for decades. In recent years, studies have mentioned tremendous pleiotropic effects of PDE5 inhibitors on gastrointestinal, urogenital, musculoskeletal, reproductive, cutaneous, and neurologic disorders. Recent data shows that PDE5 inhibition augments gastric mucosa protection, and here, we review the most recent findings regarding the use of PDE5 inhibitors for the prevention and management of PUD.
消化性溃疡病（PUD）仍然是全球范围内导致发病率和死亡率显著的原因。几乎三分之二的 PUD 病例无症状。在有症状的患者中，上腹痛是 PUD 的最常见表现症状，其表现为恶心、腹部饱满、胀气和消化不良。大多数 PUD 病例与 COX 抑制剂的使用或幽门螺杆菌感染有关，或两者兼有。PUD 的传统治疗包括使用质子泵抑制剂来减少胃酸分泌和使用抗菌药物来对抗 H. pylori。及时诊断和治疗 PUD 对于降低相关发病率和死亡率至关重要，对包括 COX 抑制剂使用者和 H. pylori 感染者在内的高危患者预防 PUD 也至关重要。PDE5 抑制剂已被用于治疗勃起功能障碍和肺动脉高压数十年。近年来，研究提到了 PDE5 抑制剂对胃肠道、泌尿生殖、肌肉骨骼、生殖、皮肤和神经系统疾病的巨大多效性作用。最近的数据表明，PDE5 抑制增强了胃黏膜的保护作用，在此，我们回顾了关于 PDE5 抑制剂用于预防和治疗 PUD 的最新发现。
